Clinical Trial

Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma

Study acronym: ICAR
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The investigators propose to study the carbonic anhydrase inhibition (acetazolamide) associated with concomitant radiochemotherapy or radioimmunotherapy in small cell lung cancer due to: 1. The over-expression of carbonic anhydrases in this type of cancer, 2. The Anti-tumor effect in preclinical acetazolamide in various tumor lines including neuroendocrine tumor lines, 3. The observed synergy between irradiation and inhibition of carbonic anhydrases, 4. Potential anti-tumor immune effect caused by decreased extracellular acidity.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2018-03-09; most recent amendment 2026-01-16.
Status change: Not Yet Recruiting → Recruiting 2019-10-28
Trial Details
NCT Number NCT03467360
Lead Sponsor Centre Antoine Lacassagne
Conditions Small Cell Lung Cancer
Enrollment 27 participants
Start Date 2019-08-02
Primary Completion 2026-10-27 (estimated)
Study Completion 2027-04-27 (estimated)
Updated on ClinicalTrials.gov 2026-01-20